Drug Trial Radar · NCT00000569
Lung Health Study II
Last checked: Nov 20, 2026Latest source record: Nov 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,116
Actual
Start
Sep 1993
Primary completion
May 1999
Study completion May 1999
Sponsor
- Lead sponsor
- University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Oct 28, 1999
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine if participants with chronic obstructive pulmonary disease, who were assigned to inhaled corticosteroids had a lower rate of decline in lung function and lower incidence of respiratory morbidity compared to participants assigned to placebo.
Conditions
- Lung Diseases
- Lung Diseases, Obstructive
- Chronic Obstructive Pulmonary Disease
Interventions
triamcinoloneDrug
1200 micrograms of triamcinolone in daily divided doses
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.